Recent Updates
Recently added Catalysts

Belite Bio, Inc

BLTEFDA catalysts, PDUFA dates & pipeline intelligence
$157.72
▼ -4.84 · -2.98%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full BLTE financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $105.8852W HIGH $200.00
Volume
94.84 K
Value Traded
15.05 M
Short % Float
3.46%
Days to Cover
10.0
+1.14%Week
+7.04%1 Month
-6.43%3 Month
+10.02%6 Month
+998.4%5 Year
+998.4%All Time

Cash Data

Unlock BLTE cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
6.35 B
EPS (TTM)
-2.53
P/E Ratio
-
Ent. Value
5.23 B
Total Shares
40.27 M
Float Shares
39.88 M
Insiders
1.80%
Institutions
22.98%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
PDUFA Date
tinlarebant (LBS-008)
Stargardt disease type 1 (STGD1)
BreakthroughPriorityFast Track+2
PDUFASmall MoleculesOphthalmology
Unlock every BLTE catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

BLTE Catalyst Timeline

Dated clinical, regulatory and corporate events for Belite Bio, Inc

Catalyst Timeline

Dated clinical, regulatory & corporate events for Belite Bio, Inc

282Total events
8Upcoming
56Tier-1 (high impact)
2022 to 2027Coverage

Upcoming catalysts 2

T1PDUFA Date
Subscribe to view catalyst details
TinlarebantFiled
T1PDUFA Date
Subscribe to view catalyst details
TinlarebantFiled

Event history 50

●Quarterly UpdateCorporate
Belite Bio reported Q3 2026 financial results
▲Stock ListingCorporate
Belite Bio uplisted from Nasdaq Capital Market to Nasdaq Global Select Market
●EU MAA SubmissionTinlarebantFiledEx-US Regulatory
MAA submissions via Access Consortium for tinlarebant in STGD1
Stargardt disease type 1 (STGD1)source ↗
●Other Regulator MilestoneTinlarebantFiledEx-US Regulatory
MAA submitted to Swissmedic via Access Consortium for tinlarebant in STGD1
Stargardt disease type 1 (STGD1)source ↗
●MHRA MilestoneTinlarebantFiledEx-US Regulatory
MAA submitted to UK MHRA via Access Consortium for tinlarebant in STGD1
Stargardt disease type 1 (STGD1)source ↗
▲Priority ReviewTinlarebantFiledRegulatory Filing
US NDA for tinlarebant in STGD1 under Priority Review
Stargardt disease type 1 (STGD1)source ↗
▲Topline ReadoutTinlarebantFiledClinical Data
Topline results from Phase 3 DRAGON study of tinlarebant in adolescent STGD1
Adolescent Stargardt Diseasesource ↗
●EU MAA SubmissionTinlarebantFiledEx-US Regulatory
MAAs submitted for tinlarebant in STGD1 in Singapore, UK and Switzerland
Stargardt disease type 1 (STGD1)source ↗
●Oral PresentationPresentation
Belite Bio Company Overview oral presentation at Euretina Innovation Spotlight
inherited and rare retinal diseasessource ↗
●Oral PresentationTinlarebantFiledPresentation
Belite Bio Company Overview oral presentation at Euretina Innovation Spotlight
Stargardt disease type 1 (STGD1)source ↗
Unlock the full BLTE catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How BLTE actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-10-10Tinlarebant (LBS-008) Phase 3 data presentation Phase 3
Unlock 10 more BLTE historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 33%
Small Cap
(rank 240 of 725)
Percentile Rank
Showing 7 of 7 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
Tinlarebant Small MoleculesNCT06388083STGD1Phase 2/3 ACTIVE NOT_RECRUITING 60Feb 1, 2028
Tinlarebant Small MoleculesNCT05949593Geographic AtrophyPhase 3 ACTIVE NOT_RECRUITING 429Aug 31, 2027
Tinlarebant Small MoleculesCompletedNCT05244304Stargardt Disease 1Phase 3 COMPLETED 104Sep 11, 2025
Tinlarebant Small MoleculesCompletedNCT05266014Stargardt DiseasePhase 1/2 COMPLETED 13Aug 15, 2023
Tinlarebant Small MoleculesCompletedNCT05667688Dry Age-related Macular DegenerationPhase 1 COMPLETED 15Jan 18, 2023
BPN-14967 Small MoleculesCompletedNCT04005807UndisclosedPhase 1 COMPLETED 40Dec 20, 2019
LBS-008 Small MoleculesCompletedNCT03735810UndisclosedPhase 1 COMPLETED 71Sep 16, 2019
Unlock the BLTE pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every BLTE program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
tinlarebant
BreakthroughPriorityFast Track+2
Stargardt disease type 1Phase 32026-05-15In the Phase 3 DRAGON trial, tinlarebant achieved a clinically meaningful 35.7% reduction in the growth rate of atrophic retinal lesions compared to placebo, demonstrating its potential efficacy in treating Stargardt disease type 1.Read MoreBelite Bio Announces Oral Presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026)Read More
Scroll for more · summaries link to the source press release
Unlock every BLTE trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock BLTE insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Scholl Hendrik PeterOfficer (Chief Medical Officer)Sell -500 14,000 held$162.04 11/12/2026
Unlock the full BLTE insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
Paradigm Biocapital Advisors LP 3.9 % (8.3 %) 193.96 M 1.14 M -7.36% ( -90.75 K)
Unlock every fund holding BLTE
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in BLTE
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see BLTE ownership
Insider and institutional ownership, quarter by quarter.

BLTE Short Interest

Shares sold short, counted twice a month.

3.46%
Short % of Float
of tradable shares sold short
1.4M
Shares Sold Short
+8.9% vs prior count
10.0 High
Days to Cover
trading days of normal volume to buy every short share back
138.7K
Avg Daily Volume
the average used for days to cover
Unlock BLTE short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock BLTE option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live BLTE option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock BLTE options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How BLTE ranks across every disease it competes in

Competitive Position is a premium feature
See how BLTE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

BLTE News

BLTE
Nov 12, 2026
BLTEFDA Updates
▲ +9%on this news

Belite Bio Reports Unaudited Third Quarter 2026 Financial Results and Provides a Corporate Update

Belite Bio reported its third quarter 2026 financial results, highlighting the FDA's priority review of its NDA for tinlarebant in Stargardt disease type 1. The company also submitted applications in Japan and other countries. Despite a significant net loss of $30.3 million, Belite Bio is advancing its clinical trials and regulatory submissions.

Read more →
BLTE
Nov 5, 2026
BLTEConferences/Events
▼ -7%on this news

Belite Bio to Host Webcast on November 12, 2026, to Discuss Third Quarter 2026 Financial Results

Belite Bio will host a webcast on November 12, 2026, to discuss its third quarter financial results and provide a business update. The company focuses on therapies for degenerative retinal diseases and has positive trial results for its lead candidate, tinlarebant. The webcast will be accessible via a provided link.

Read more →
BLTE
Oct 19, 2026
BLTEGeneral

Belite Bio Announces Uplisting to the Nasdaq Global Select Market

Belite Bio has announced its uplisting to the Nasdaq Global Select Market, effective October 19, 2026. This transition signifies the company's compliance with higher financial standards and aims to enhance its visibility among institutional investors. The company is focused on developing treatments for degenerative retinal diseases, including Stargardt disease, with its lead candidate, tinlarebant, currently in advanced clinical trials.

Read more →
BLTE
Oct 14, 2026
BLTEFDA Updates

Belite Bio Announces Multi-Market Submission of Marketing Authorization Applications Via the Access Consortium Pathway for Tinlarebant for the Treatment of Stargardt Disease Type 1

Belite Bio has submitted Marketing Authorization Applications for tinlarebant to treat Stargardt Disease Type 1 in Singapore, the UK, and Switzerland. This submission, made through the Access Consortium, aims to expedite the approval process. If approved, tinlarebant will be the first treatment for this condition in these regions. The drug is also under review in the U.S. and Japan.

Read more →
BLTE
Sep 29, 2026
BLTEConferences/Events

Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences

Belite Bio, a clinical-stage drug development company, announced that it will present data at two upcoming medical conferences in Vienna, Austria. The presentations will focus on the company's lead candidate, Tinlarebant, which targets Stargardt disease. The drug has received various designations from the FDA, highlighting its potential in treating retinal diseases.

Read more →
BLTE
Sep 8, 2026
BLTEFDA Updates

Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1

Belite Bio announced the submission of a New Drug Application for tinlarebant to treat Stargardt Disease Type 1 in Japan. This submission follows a similar application in the U.S. and aims to provide the first-ever treatment for this condition. Tinlarebant has received Sakigake designation, allowing for expedited review due to the significant unmet medical need.

Read more →
BLTE
Sep 1, 2026
BLTEConferences/Events

Belite Bio to Participate in Four Upcoming Investor Conferences

Belite Bio, a clinical-stage drug development company, will participate in four investor conferences in September 2026. These events include the Wells Fargo Healthcare Conference, Cantor Global Healthcare Conference, Morgan Stanley Global Healthcare Conference, and H.C. Wainwright Investment Conference. The company aims to showcase its advancements in therapies for degenerative retinal diseases.

Read more →
BLTE
Aug 24, 2026
BLTEConferences/Events

Belite Bio to Host Virtual Commercial Day on September 2, 2026

Belite Bio will host a Virtual Commercial Day on September 2, 2026, focusing on Stargardt disease type 1 (STGD1) and the potential of their drug tinlarebant. The event will feature experts in ophthalmology and discuss the unmet needs in STGD1 treatment. The FDA has accepted the New Drug Application for tinlarebant, with a Priority Review status and a Prescription Drug User Fee Act date set for February 12, 2027.

Read more →
BLTE
Aug 13, 2026
BLTEFDA Updates
▼ -7.1%on this news

Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update

Belite Bio reported its second quarter 2026 financial results, highlighting the FDA's acceptance of the New Drug Application for tinlarebant for Stargardt disease type 1 with a Priority Review status. The company presented encouraging data from the Phase 3 DRAGON trial at the ASRS Annual Meeting. Despite a net loss of $28.4 million, Belite is preparing for the drug's potential launch and expansion of its commercial operations.

Read more →
BLTE
Aug 11, 2026
BLTEFDA Updates

Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1

Belite Bio announced that the FDA accepted its New Drug Application for tinlarebant to treat Stargardt Disease Type 1. The agency granted Priority Review designation, setting a target action date of February 12, 2027. Clinical data showed a 35.7% reduction in the growth rate of atrophic retinal lesions compared to placebo. If approved, this would be the first treatment for this rare inherited retinal disease.

Read more →
BLTE
Aug 6, 2026
BLTEConferences/Events

Belite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial Results

Belite Bio, a clinical-stage drug development company, will host a webcast on August 13, 2026, to discuss its second-quarter financial results and provide a business update. The company focuses on therapeutics for degenerative retinal diseases, with its lead candidate, tinlarebant, currently in multiple trials. The webcast aims to inform stakeholders about the company's progress and financial health.

Read more →
BLTE
Jul 20, 2026
BLTEFDA Updates

Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1

Belite Bio announced positive secondary endpoint data from its Phase 3 DRAGON trial of tinlarebant for Stargardt disease type 1 at the ASRS Annual Meeting. The treatment demonstrated a significant reduction in retinal lesion growth and stable qAF values compared to placebo. The company has completed its New Drug Application to the FDA for tinlarebant.

Read more →
BLTE
Jul 15, 2026
BLTEConferences/Events

Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference

Belite Bio, Inc. will participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference on July 22, 2026. The company focuses on developing therapies for degenerative retinal diseases, including Stargardt disease and geographic atrophy. Their lead candidate, tinlarebant, has met primary endpoints in a Phase 3 trial and is undergoing further evaluation.

Read more →
BLTE
Jul 6, 2026
BLTEConferences/Events
▲ +5%on this news

Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium

Belite Bio, a clinical-stage drug development company, will participate in the Piper Sandler Virtual Ophthalmology Investor Symposium on July 9, 2026. The company focuses on developing therapeutics for degenerative retinal diseases, including Stargardt disease and geographic atrophy. Their lead candidate, tinlarebant, has completed a Phase 3 trial and is currently undergoing further evaluations.

Read more →
BLTE
Jun 13, 2026
BLTEFDA Updates

Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1

Belite Bio has completed the rolling submission of a New Drug Application for tinlarebant, an oral therapy aimed at treating Stargardt disease type 1. This submission, initiated under Breakthrough Therapy Designation, addresses a significant unmet medical need as there are currently no approved treatments for this rare retinal disease. The application will undergo a 60-day review by the FDA.

Read more →
BLTE
Jun 2, 2026
BLTEConferences/Events
▼ -8.2%on this news

Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Belite Bio, a clinical-stage drug development company, will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026. The company focuses on developing therapeutics for degenerative retinal diseases and has made progress with its lead candidate, tinlarebant, which has met primary endpoints in clinical trials. The event will be accessible via webcast.

Read more →
BLTE
May 20, 2026
BLTEFDA Updates

Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update

Belite Bio reported its unaudited financial results for Q1 2026, highlighting a rolling NDA submission for tinlarebant aimed at treating Stargardt disease type 1 (STGD1). The company has completed hiring for its commercial leadership team and has a strong cash position of $798.6 million. However, it also reported a net loss of $26.9 million, reflecting increased R&D expenses associated with clinical trials.

Read more →
BLTE
May 18, 2026
BLTEFDA Updates

Belite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in Switzerland

Belite Bio has received orphan drug status for its lead candidate, tinlarebant, for the treatment of Stargardt disease from Swissmedic. This designation follows the successful Phase 3 DRAGON trial, where tinlarebant achieved a 35.7% reduction in retinal lesion growth. The company is also progressing with a rolling NDA submission to the FDA, expected to complete by Q2 2026.

Read more →

About Belite Bio, Inc

41 employees belitebio.com
BIOPHARMAWATCH ELITE
Trade the next BLTE catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime